SCHEMBL198146

SCHEMBL198146

CC(C)(C)c1cc(C(C)(C)C)c(Br)c(C(C)(C)C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.42
GABRB2 P47870 1/20 0.42
POLB P06746 2/20 0.39
ALDH1A1 P00352 5/20 0.38
ALOX15 P16050 4/20 0.38
CYP1A2 P05177 3/20 0.38
KDM4E B2RXH2 3/20 0.38
MAPT P10636 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ATP2A2 P16615 1/20 0.38
ATP2A3 Q93084 1/20 0.38
HSP90AA1 P07900 1/20 0.36
CA2 P00918 2/20 0.35
CA1 P00915 1/20 0.35
CYP2C19 P33261 3/20 0.34
CYP2C9 P11712 3/20 0.34
HIF1A Q16665 2/20 0.34
CYP2D6 P10635 1/20 0.34
TSHR P16473 3/20 0.34
CYP3A4 P08684 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1041996 0.89 GABBR2 (0.36) GABRA1GABRB2POLBALDH1A1ALOX15
SCHEMBL17594925 0.87 POLB (0.44) GABRA1GABRB2POLBALDH1A1ALOX15
SCHEMBL28469471 0.84 ALDH1A1 (0.46) GABRA1GABRB2POLBALDH1A1ALOX15
SCHEMBL1039800 0.84 HSP90AA1 (0.35) GABRA1GABRB2POLBALDH1A1ALOX15
SCHEMBL18802719 0.82 GABRA1 (0.42) GABRA1GABRB2POLBALDH1A1ALOX15
SCHEMBL3620122 0.80 CYP3A4 (0.41) GABRA1GABRB2POLBALDH1A1ALOX15
SCHEMBL29707205 0.80 HTT (0.39) GABRA1GABRB2POLBALDH1A1CYP1A2
SCHEMBL2293546 0.80 HTT (0.39) GABRA1GABRB2POLBALDH1A1CYP1A2
SCHEMBL1086377 0.80 POLB (0.52) GABRA1GABRB2POLBALDH1A1ALOX15
SCHEMBL4572705 0.80 ALDH1A1 (0.39) GABRA1GABRB2POLBALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254150-A1 CONFORMATIONALLY RESTRICTED SULFONATE BASED PHOSPHINE LIGANDS FOR HINDERED SUZUKI COUPLING REACTIONS TCG GreenChem Inc. (US) 2024-08-01 US claimed
US-20260114115-A1 COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE SAMSUNG ELECTRONICS CO LTD (KR) 2026-04-23 US disclosed
US-20260042791-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2026-02-12 US disclosed
CN-119859147-A Compound and organic electroluminescent device 三星电子株式会社 2025-04-22 CN disclosed
US-12281129-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2025-04-22 US disclosed
US-12250875-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2025-03-11 US disclosed
US-20240254150-A1 CONFORMATIONALLY RESTRICTED SULFONATE BASED PHOSPHINE LIGANDS FOR HINDERED SUZUKI COUPLING REACTIONS TCG GreenChem Inc. (US) 2024-08-01 US disclosed
US-20240122061-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2024-04-11 US disclosed
US-11930699-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2024-03-12 US disclosed
US-11737349-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2023-08-22 US disclosed
EP-1758853-B1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES LILLY CO ELI (US) 2010-01-20 EP disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 US disclosed
EP-1881976-A1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS Amgen Inc., (US) 2008-01-30 EP disclosed
US-20070249688-A1 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses ELI LILLY AND COMPANY (US) 2007-10-25 US disclosed
EP-1758853-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2007-03-07 EP disclosed
WO-2006116713-A1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS AMGEN INC. (US) 2006-11-02 WO disclosed
WO-2005123668-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2005-12-29 WO disclosed
US-3988369-A Process and reactant for halogenating organic compounds PEARSON DONALD E 1976-10-26 US disclosed
US-3972872-A BACTERICIDE, ANIMAL FEED SUPPLEMENT PFIZER INC. (US) 1976-08-03 US disclosed
US-3933797-A 6-[α-(ω-QUANIDINOALKANOYLAMIDO)ACYLAMIDO]PENICILLANIC ACIDS PFIZER INC. (US) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254150-A1 CONFORMATIONALLY RESTRICTED SULFONATE BASED PHOSPHINE LIGANDS FOR HINDERED SUZUKI COUPLING REACTIONS STS, PTPRS, PFKFB1 GABRA1 1170/4885GABRB2 1347/4885POLB 1179/4885
US-12250875-B2 Organic electroluminescent materials and devices L1CAM, SOD1, EPCAM GABRA1 2515/4885GABRB2 2277/4885POLB 1748/4885
US-20260114115-A1 COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE CCNL2, ARL1, TRMT1L GABRA1 3970/4885GABRB2 4498/4885POLB 2172/4885
US-12281129-B2 Organic electroluminescent materials and devices OCIAD1, OCIAD2, OSBP GABRA1 3648/4885GABRB2 3920/4885POLB 1546/4885
US-11737349-B2 Organic electroluminescent materials and devices OCIAD2, OCIAD1, OTC GABRA1 4384/4885GABRB2 4127/4885POLB 1878/4885
US-20080312232-A1 Substituted amide derivatives and methods of use HGF, HGFAC, MET GABRA1 2699/4885GABRB2 2340/4885POLB 1063/4885
US-20070249688-A1 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses GLP1R, GCGR, GIPR GABRA1 461/4885GABRB2 642/4885POLB 4801/4885
US-20260042791-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES LBR, GLRA1, MSL1 GABRA1 820/4885GABRB2 1286/4885POLB 2997/4885
US-11930699-B2 Organic electroluminescent materials and devices L1CAM, EPCAM, LEF1 GABRA1 2164/4885GABRB2 1765/4885POLB 1413/4885
US-20240122061-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES L1CAM, SOD1, EPCAM GABRA1 2515/4885GABRB2 2277/4885POLB 1748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.